Arcellx(US:ACLX) 智通财经网·2025-12-23 07:17Core Viewpoint - Wells Fargo initiates coverage and assigns an "overweight" rating to Arcellx (ACLX.US), highlighting its experimental CAR-T therapy "anito-cel" as a potential cornerstone in the management of multiple myeloma, which could significantly reshape treatment paradigms [1][4] Group 1: Company Overview - Arcellx is a clinical-stage biotechnology company focused on developing cell therapy products for cancer and certain autoimmune conditions using its proprietary D-Domain technology platform [3] - The company is collaborating with Kite Pharma, a subsidiary of Gilead Sciences (GILD.US), for the development and commercialization of anito-cel [2][3] Group 2: Product Potential - Anito-cel is a BCMA-targeted autologous CAR-T cell therapy designed for relapsed/refractory multiple myeloma, with expectations for significant market share in the 4L+ BCMA CAR-T market due to its attractive efficacy and safety profile compared to existing approved products [1][2][4] - Analysts project peak sales for anito-cel in the fourth-line setting could reach $1.6 billion, with approximately $690 million attributed to Arcellx, and potentially $3.8 billion after gaining second-line approval, with around $1.5 billion for Arcellx [2] Group 3: Market Impact - The anticipated approval of anito-cel in 2026 could lead to rapid market penetration, fundamentally altering the competitive landscape for BCMA-targeted therapies in multiple myeloma [5] - Despite strong recent clinical trial data from Johnson & Johnson's (JNJ.US) Tecvayli and Darzalex, approximately 30% of patients show extreme resistance to Darzalex, which may limit its effectiveness in certain treatment scenarios [2]